Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm Metastasis 3Melanoma 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Virus Diseases 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Pain 1Neuroectodermal Tumors 1Neuroblastoma 1Nervous System Diseases 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Insulin-Like Growth Factor I, Resistance To 1Humoral Hypercalcemia Of Malignancy 1Gliosarcoma 1Glioma 1Glioblastoma 1Epstein-Barr Virus Infections 1Disease 1

Interventions

Rituximab 168Cyclophosphamide 142Peripheral Blood Stem Cell Transplantation 84fludarabine phosphate 68Filgrastim 64Etoposide 63Radiotherapy 55Vincristine 47Prednisone 45Mycophenolic Acid 44Melphalan 40Whole-Body Irradiation 39Cyclosporine 39Busulfan 39Tacrolimus 36Doxorubicin 34Cytarabine 33Lenalidomide 29Carmustine 28Antilymphocyte Serum 28Methotrexate 27Methylprednisolone 26Bortezomib 26Bendamustine Hydrochloride 26sargramostim 21ibritumomab tiuxetan 20obinutuzumab 19ibrutinib 18fludarabine 18Dexamethasone 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Follicular × Antibodies, Monoclonal × Clear all
NCT00989586 2017-02-06

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
35 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡